Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
absorption, ASU, average, bargaining, BBB, bear, bond, brought, Circuit, clearance, closure, concurrently, Cook, dedesignated, denied, disclaim, discovery, division, draft, Erosion, EU, exclusive, explore, expressly, fact, FASB, intelligent, IQ, larger, lieu, LVP, matter, meaningful, meaningfully, member, merchant, monetize, monthly, Novum, OECD, phasing, pillar, prepay, primary, proceed, pump, qui, reconciling, Red, reduction, region, relationship, release, reorganization, retain, rollover, Sea, seek, settlement, softer, spread, stable, successfully, Taiwan, tam, terrorism, threshold, Topic, training, tranche, ultimately, unknown, unsealed, widespread, wind
Removed:
administered, APAC, arising, assuming, August, broader, calculate, California, cardiology, cease, Cherry, common, comparison, compel, compliant, consisting, Consumer, consummated, continuation, continued, cyclical, delaying, determination, digital, discontinuation, disease, distinguish, distributor, diverted, EMEA, EURIBOR, experiencing, Fayette, field, focused, footnote, foreseeable, Georgia, guaranteed, harm, HD, Hill, improperly, interbank, Kingdom, led, legacy, LIBOR, licensing, lifting, liquid, London, marketed, MDL, modified, necessitating, NJ, North, offered, Ohio, open, opiate, orally, Overnight, Pacific, past, physical, Prescription, preventing, Privacy, pursuit, recovery, recruit, reducing, remediation, replace, responsive, restricting, South, spending, stage, submit, subscription, successor, supported, targeting, Unregistered, warranty, widely, working
Financial report summary
?Competition
Axogen • ThermoGenesis • AIM ImmunoTech • Sangamo Therapeutics • United Health Products • Edwards Lifesciences • Curis • Lemaitre Vascular • Nephros • GlycoMimeticsRisks
- The proposed spinoff of our Kidney Care business may not be completed on the terms, structure or timeline we have announced, if at all.
- We may continue to experience difficulties with our integration of Hillrom or fail to realize the anticipated benefits of the Hillrom acquisition.
- If our business strategy and development activities are unsuccessful, our business, results of operations, financial condition and cash flows could be adversely affected.
- Global economic conditions, including inflation and supply chain disruptions, have adversely affected, and could continue to adversely affect, our operations.
- Our operating results and financial condition have, and may in the future, fluctuate.
- We may not achieve our financial goals.
- We incurred a substantial amount of debt in connection with the Hillrom acquisition, which could adversely affect our business, results of operations, financial condition and cash flows.
- Changes in foreign currency exchange rates and interest rates have, and may in the future have, an adverse effect on our results of operations, financial condition, cash flows and liquidity.
- Our common stock price has fluctuated significantly and may continue to do so in the future.
- Future material impairments in the value of our goodwill, intangible assets and other long-lived assets would negatively affect our operating results.
- If we are unable to successfully introduce or monetize new and existing products or services, or fail to keep pace with changing consumer preferences and needs or advances in technology, our business, results of operations, financial condition and cash flows could be adversely affected.
- Issues with product quality could have an adverse effect on our business or cause a loss of customer confidence in us or our products, among other negative consequences.
- There is substantial competition in the product markets in which we operate and the risk of declining demand and pricing pressures could adversely affect our business, results of operations, financial condition and cash flows.
- Pandemics and other public health emergencies, or the fear thereof, have had, and may in the future have, a material adverse effect on our business. The nature and extent of future impacts are uncertain and unpredictable.
- If we fail to attract, develop, retain and engage key employees, our business may suffer.
- We may not be successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions, and might experience business disruptions and adverse tax consequences associated with restructuring, realignment and cost reduction activities.
- If we are unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective price or if we experience other manufacturing, sterilization, supply or distribution difficulties, our business, results of operations, financial condition and cash flows may be adversely affected.
- Climate change, or legal, regulatory or market measures to address climate change, could adversely affect our business, results of operations, financial condition and cash flows.
- Breaches and breakdowns affecting our information technology systems or protected information, including from cyber security breaches and data leakage, could have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and competitive position.
- We are subject to risks associated with doing business globally.
- We are subject to a number of laws and regulations, non-compliance with which could adversely affect our business, results of operations, financial condition and cash flows, and we are susceptible to a changing regulatory environment.
- Increasing regulatory focus on privacy and cybersecurity issues and expanding laws could impact our business and expose us to increased liability.
- If reimbursement or other payment for our current or future products is reduced or modified in the United States or in foreign countries, including through the implementation or repeal of government-sponsored
- healthcare reform or other similar actions, cost containment measures, or there are changes to policies with respect to pricing, taxation or rebates, our business could suffer.
- We could be subject to fines or damages and possible exclusion from participation in federal or state healthcare programs if we fail to comply with the laws and regulations applicable to our business.
- If we are unable to protect or enforce our patents or other proprietary rights, or if we become subject to claims or litigation alleging infringement of the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.
- Changes in tax laws or exposure to additional income tax liabilities may have a negative impact on our operating results.
- We are party to a number of pending lawsuits and other disputes which may have an adverse impact on our business, results of operations, financial condition and cash flows.
- Our Amended and Restated Bylaws designate certain courts in the State of Delaware or the federal district courts of the United States will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
Management Discussion
- For the three months ended March 31, 2024, net income attributable to Baxter stockholders was $37 million, or $0.07 per diluted share. For the three months ended March 31, 2023, net loss from continuing operations attributable to Baxter stockholders was $1 million, or $0.00 per diluted share, and net income from discontinued operations was $45 million, or $0.09 per diluted share. For the three months ended March 31, 2024, our results included special items that decreased net income attributable to Baxter stockholders by $294 million, or $0.58 per diluted share. For the three months ended March 31, 2023, our results included special items that decreased income from continuing operations attributable to Baxter stockholders by $249 million, or $0.49 per diluted share, and decreased net income from discontinued operations by $4 million, or $0.01 per diluted share. See the subsection entitled “Special Items” for information about special items for all periods presented.